Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence

European Journal of Endocrinology

Volumn 166, Issue 6, 2012, Pages 1003-1011

  Cibula, David ^a   Skrenkova, Jana ^a   Hill, Martin ^b   Stepan, Jan J ^a,c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

^c INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIFEDIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; ESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; GESTODENE; ORAL CONTRACEPTIVE AGENT; PROCOLLAGEN;

ADOLESCENCE; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIETARY INTAKE; DRUG DOSE COMPARISON; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; FEMALE; FEMUR; FEMUR NECK; FOOD FREQUENCY QUESTIONNAIRE; HORMONAL CONTRACEPTION; HUMAN; LOW DRUG DOSE; LUMBAR SPINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIUS; SMOKING; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; CONFOUNDING FACTORS (EPIDEMIOLOGY); CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; DENSITOMETRY; DRUG ADMINISTRATION SCHEDULE; ELECTROCHEMISTRY; ETHINYL ESTRADIOL; FEMALE; FEMUR; FEMUR NECK; HUMANS; IMMUNOASSAY; LUMBAR VERTEBRAE; LUMINESCENCE; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; PROSPECTIVE STUDIES; RADIUS; RESEARCH DESIGN; TIME FACTORS; VITAMIN D; YOUNG ADULT;

EID: 84862726753     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-1047     Document Type: Article

References (41)

1. Beck-Peccoz P & Persani L. Premature ovarian failure. Orphanet Journal of Rare Diseases 2006 1 9. (doi:10.1186/1750-1172-1-9)
2. Doren M, Nilsson JA & Johnell O. Effects of specific postmenopausal hormone therapies on bone mineral density in postmenopausal women: a meta-analysis. Human Reproduction 2003 18 1737-1746. (doi:10.1093/humrep/deg315)
3. Castelo-Branco C, Vicente JJ, Pons F, Martinez de Osaba MJ, Casals E & Vanrell JA. Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. Journal of Reproductive Medicine 2001 46 875-879.
4. Hergenroeder AC, Smith EO, Shypailo R, Jones LA, Klish WJ & Ellis K. Bone mineral changes in youngwomen with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. American Journal of Obstetrics and Gynecology 1997 176 1017-1025. (doi:10.1016/S0002- 9378(97)70396-X)
5. Warren MP, Miller KK, Olson WH, Grinspoon SK & Friedman AJ. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study. Contraception 2005 72 206-211. (doi:10.1016/j.contraception.2005.03.007)
6. Reed SD, Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE &Ott SM. Longitudinal changes in bone density in relation to oral contraceptive use. Contraception 2003 68 177-182. (doi:10.1016/S0010-7824(03)00147-1)
7. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI & Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstetrics and Gynecology 2004 103 899-906. (doi:10.1097/01.AOG.0000117082. 49490.d5)
8. Endrikat J, Mih E, Dusterberg B, Land K, Gerlinger C, Schmidt W &Felsenberg D. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or 30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception 2004 69 179-187. (doi:10.1016/j.contraception.2003.10.002)
9. Nappi C, Di Spiezio Sardo A, Greco E, Tommaselli GA, Giordano E &Guida M. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density. Obstetrics and Gynecology 2005 105 53-60. (doi:10.1097/01.AOG.0000148344.26475.fc)
10. Gambacciani M, Ciaponi M, Cappagli B, Benussi C &Genazzani AR. Longitudinal evaluation of perimenopausal femoral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Osteoporosis International 2000 11 544-548. (doi:10.1007/s001980070099)
11. Gambacciani M, Spinetti A, Taponeco F, Cappagli B, Piaggesi L &Fioretti P. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstetrics and Gynecology 1994 83 392-396. (Pubitemid 24067808)
12. Theintz G, Buchs B, Rizzoli R, Slosman D, Clavien H, Sizonenko PC & Bonjour JP. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. Journal of Clinical Endocrinology and Metabolism 1992 75 1060-1065. (doi:10.1210/jc.75.4.1060)
13. Polatti F, Perotti F, Filippa N, Gallina D & Nappi RE. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 1995 51 221-224. (doi:10.1016/0010-7824(95)00036-A)
14. Register TC, Jayo MJ & Jerome CP. Oral contraceptive treatment inhibits the normal acquisition of bone mineral in skeletally immature young adult female monkeys. Osteoporosis International 1997 7 348-353. (doi:10.1007/BF01623776)
15. Cromer BA, Stager M, Bonny A, Lazebnik R, Rome E, Ziegler J &Debanne SM. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. Journal of Adolescent Health 2004 35 434-441. (doi:10.1016/j.jadohealth.2004.07.005)
16. Lloyd T, Taylor DS, Lin HM, Matthews AE, Eggli DF & Legro RS. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study. Fertility and Sterility 2000 74 734-738. (doi:10.1016/S0015-0282(00)00719-6)
17. Beksinska ME, Kleinschmidt I, Smit JA & Farley TM. Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception. Contraception 2007 75 438-443. (doi:10.1016/j.contraception.2007.02.001)
18. Cromer BA, Bonny AE, Stager M, Lazebnik R, Rome E, Ziegler J, Camlin-Shingler K & Secic M. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertility and Sterility 2008 90 2060-2067. (doi:10.1016/j.fertnstert.2007.10.070)
19. Gargano V, Massaro M, Morra I, Formisano C, Di Carlo C &Nappi C. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2008 78 10-15. (doi:10.1016/j. contraception.2008.01.016)
20. Angus RM, Sambrook PN, Pocock NA & Eisman JA. A simple method for assessing calcium intake in Caucasian women. Journal of the American Dietetic Association 1989 89 209-214. (Pubitemid 19061840)
21. Meloun M, Hill M, Militky J & Kupka K. Transformation in the PC-aided biochemical data analysis. Clinical Chemistry and Laboratory Medicine 2000 38 553-559. (doi:10.1515/CCLM.2000.081)
22. Meloun M, Hill M& Vcelakova-Havlikova H. Minimizing the effects of multicollinearity in the polynomial regression of age relationships and sex differences in serum levels of pregnenolone sulfate in healthy subjects. Clinical Chemistry and Laboratory Medicine 2009 47 464-470. (doi:10.1515/CCLM. 2009.104)
23. Meloun M, Militky J, Hill M & Brereton RG. Crucial problems in regression modelling and their solutions. Analyst 2002 127 433-450. (doi:10.1039/b110779h)
24. Bass S, Delmas PD, Pearce G, Hendrich E, Tabensky A & Seeman E. The differing tempo of growth in bone size, mass, and density in girls is region-specific. Journal of Clinical Investigation 1999 104 795-804. (doi:10.1172/JCI7060)
25. Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR &Kimmel DB. Bone gain in young adult women. Journal of the American Medical Association 1992 268 2403-2408. (doi:10.1001/jama.1992.03490170075028)
26. Clark PA & Rogol AD. Growth hormones and sex steroid interactions at puberty. Endocrinology and Metabolism Clinics of North America 1996 25 665-681. (doi:10.1016/S0889-8529(05)70346-7)
27. Coutant R, de Casson FB, Rouleau S, Douay O, Mathieu E, Gatelais F, Bouhours-Nouet N, Voinot C, Audran M & Limal JM. Divergent effect of endogenous and exogenous sex steroids on the insulin-like growth factor I response to growth hormone in short normal adolescents. Journal of Clinical Endocrinology and Metabolism 2004 89 6185-6192. (doi:10.1210/jc.2004-0814)
28. Juul A. The effects of oestrogens on linear bone growth. Human Reproduction Update 2001 7 303-313. (doi:10.1093/humupd/7.3.303)
29. Veldhuis JD, Anderson SM, Patrie JT & Bowers CY. Estradiol supplementation in postmenopausal women doubles rebound-like release of growth hormone (GH) triggered by sequential infusion and withdrawal of somatostatin: evidence that estrogen facilitates endogenous GH-releasing hormone drive. Journal of Clinical Endocrinology and Metabolism 2004 89 121-127. (doi:10.1210/jc.2003-031291)
30. Riggs BL, Khosla S & Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocrine Reviews 2002 23 279-302. (doi:10.1210/er.23.3.279)
31. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocrine Reviews 2000 21 115-137. (doi:10.1210/er.21.2.115)
32. Jarvinen TL, Kannus P & Sievanen H. Estrogen and bone - a reproductive and locomotive perspective. Journal of Bone and Mineral Research 2003 18 1921-1931. (doi:10.1359/jbmr.2003.18.11.1921)
33. Wang Q, Nicholson PH, Suuriniemi M, Lyytikainen A, Helkala E, Alen M, Suominen H & Cheng S. Relationship of sex hormones to bone geometric properties and mineral density in early pubertal girls. Journal of Clinical Endocrinology and Metabolism 2004 89 1698-1703. (doi:10.1210/jc.2003-031113)
34. Hartard M, Kleinmond C, Kirchbichler A, Jeschke D, Wiseman M, Weissenbacher ER, Felsenberg D & Erben RG. Age at first oral contraceptive use as a major determinant of vertebral bone mass in female endurance athletes. Bone 2004 35 836-841. (doi:10.1016/j.bone.2004.05.017)
35. Tamaki J, Iki M, Sato Y, Kajita E, Kagamimori S, Kagawa Y &Yoneshima H. Smoking among premenopausal women is associated with increased risk of low bone status: the JPOS Study. Journal of Bone and Mineral Metabolism 2010 28 320-327. (doi:10.1007/s00774-009-0129-8)
36. Taes Y, Lapauw B, Vanbillemont G, Bogaert V, De Bacquer D, Goemaere S, Zmierczak H & Kaufman JM. Early smoking is associated with peak bone mass and prevalent fractures in young, healthy men. Journal of Bone and Mineral Research 2010 25 379-387. (doi:10.1359/jbmr.090809)
37. Pikkarainen E, Lehtonen-Veromaa M, Mottonen T, Kautiainen H &Viikari J. Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception 2008 78 226-231. (doi:10.1016/j.contraception.2008.05.002)
38. Nappi C, Di Spiezio Sardo A, Acunzo G, Bifulco G, Tommaselli GA, Guida M & Di Carlo C. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2003 67 355-359. (doi:10.1016/S0010-7824(03)00025-8)
39. Liu JM, Zhao HY, Ning G, Chen Y, Zhang LZ, Sun LH, Zhao YJ, Xu MY & Chen JL. IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women. Journal of Bone and Mineral Metabolism 2008 26 159-164. (doi:10.1007/s00774-007-0799-z)
40. Riggs BL, Khosla S & Melton LJ III. The assembly of the adult skeleton during growth and maturation: implications for senile osteoporosis. Journal of Clinical Investigation 1999 104 671-672. (doi:10.1172/JCI8184)
41. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva: World Health Organisation, World Health Organisation Technical Report Series 1994 843 1-129.